Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Neutral
Balance Sheet
Very Strong
Website
N/ATelephone
N/A
Address
Description
Biome Australia Ltd. engages in the research, development, manufacture, and distribution of evidence-based products linking the gut and human health. It offers live biotherapeutics products and complementary medicines under the Activated Probiotic brand. The company was founded by Blair Vega Norfolk on July 6, 2018 and is headquartered in Collingwood, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.1 - 0.73
Trade Value (12mth)
AU$42,853.00
1 week
-19.85%
1 month
-2.78%
YTD
128.26%
1 year
446.87%
All time high
0.73
EPS 3 yr Growth
-3.200%
EBITDA Margin
-42.30%
Operating Cashflow
-$3m
Free Cash Flow Return
-61.30%
ROIC
-54.00%
Interest Coverage
-97.70
Quick Ratio
1.30
Shares on Issue (Fully Dilluted)
203m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
15 July 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
05 July 24 |
Application for quotation of securities - BIO
×
Application for quotation of securities - BIO |
05 July 24 |
Secondary Trading Notice
×
Secondary Trading Notice |
01 July 24 |
Biome Achieves Record Sales Revenue in FY24
×
Biome Achieves Record Sales Revenue in FY24 |
21 June 24 |
Application for quotation of securities - BIO
×
Application for quotation of securities - BIO |
21 June 24 |
Secondary Trading Notice
×
Secondary Trading Notice |
14 June 24 |
Application for quotation of securities - BIO
×
Application for quotation of securities - BIO |
14 June 24 |
Secondary Trading Notice
×
Secondary Trading Notice |
12 June 24 |
Biome expects to exceed FY24 forecast
×
Biome expects to exceed FY24 forecast |
29 May 24 |
International Market Update and Health Canada approvals
×
International Market Update and Health Canada approvals |
11 April 24 |
Non-Deal Investor Presentation April 2024
×
Non-Deal Investor Presentation April 2024 |
11 April 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
10 April 24 |
Application for quotation of securities - BIO
×
Application for quotation of securities - BIO |
10 April 24 |
Secondary Trading Notice
×
Secondary Trading Notice |
02 April 24 |
First Quarter of Positive Underlying Cash Flow
×
First Quarter of Positive Underlying Cash Flow |
08 March 24 |
Notification regarding unquoted securities - BIO
×
Notification regarding unquoted securities - BIO |
07 March 24 |
Issue of Options
×
Issue of Options |
07 March 24 |
Proposed issue of securities - BIO
×
Proposed issue of securities - BIO |
22 February 24 |
Appendix 4D & Half Yearly Report
×
Appendix 4D & Half Yearly Report |
22 February 24 |
Biome Releases First Half FY2024 Results
×
Biome Releases First Half FY2024 Results |
15 February 24 |
Application for quotation of securities - BIO
×
Application for quotation of securities - BIO |
15 February 24 |
Secondary Trading Notice
×
Secondary Trading Notice |
07 February 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
22 January 24 |
Quarterly Activities & Cashflow Report
×
Quarterly Activities & Cashflow Report |
15 January 24 |
Biome to launch into UK and Ireland health retail
×
Biome to launch into UK and Ireland health retail |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.